These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 22386741)

  • 1. Fourteen years in resistance.
    Livermore DM
    Int J Antimicrob Agents; 2012 Apr; 39(4):283-94. PubMed ID: 22386741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Carbapenemases in gram-negative bacteria. Current data and trends of resistance resulting from the work of national reference centres].
    Kaase M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 Nov; 55(11-12):1401-4. PubMed ID: 23114438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan.
    Lee SC; Huang SS; Lee CW; Fung CP; Lee N; Shieh WB; Siu LK
    BMC Infect Dis; 2007 Jul; 7():79. PubMed ID: 17640342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006).
    Rhomberg PR; Deshpande LM; Kirby JT; Jones RN
    Diagn Microbiol Infect Dis; 2007 Dec; 59(4):425-32. PubMed ID: 17662557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology of infections caused by multiresistant gram-negatives: ESBLs, MBLs, panresistant strains.
    Rossolini GM; Mantengoli E; Docquier JD; Musmanno RA; Coratza G
    New Microbiol; 2007 Jul; 30(3):332-9. PubMed ID: 17802921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of resistance tendency of bloodstream-infecting pathogens in China].
    Lü Y; Li Y; Xue F; Zhang XZ; Hu YJ; Jin YF; Chu YZ; Hu ZD; Zhao JH; Pan SY; Zhao WS; Hu BJ; Yu YS; Deng QL; Yang J; Li Y; Liu WE; Lü XJ; Yang YJ; Zhou L; Dong F; Fu WL; Xu XL; Pei FY; Yang B; Meng L; Ji P; Wang S
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Jun; 36(6):411-9. PubMed ID: 24103203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
    Dowzicky MJ; Park CH
    Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Study on prevalence and molecular mechanisms of antibacterial resistance in Gram-negative pathogens of nosocomial infections in hospitals of Moscow and Perm'].
    Mudrak DE; Ikriannikova LN; Sidorenko SV; Il'ina EN
    Antibiot Khimioter; 2007; 52(7-8):10-6. PubMed ID: 18986019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacteriologic profile and antibiogram of blood culture isolates from a children's hospital in Kabul.
    Tariq TM
    J Coll Physicians Surg Pak; 2014 Jun; 24(6):396-399. PubMed ID: 24953929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tigecycline activity: low resistance rates but problematic disc breakpoints revealed by a multicentre sentinel survey in the UK.
    Hope R; Mushtaq S; James D; Pllana T; Warner M; Livermore DM;
    J Antimicrob Chemother; 2010 Dec; 65(12):2602-9. PubMed ID: 20930043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of multidrug-resistant Gram-negative infections in children.
    Hsu AJ; Tamma PD
    Clin Infect Dis; 2014 May; 58(10):1439-48. PubMed ID: 24501388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Has the era of untreatable infections arrived?
    Livermore DM
    J Antimicrob Chemother; 2009 Sep; 64 Suppl 1():i29-36. PubMed ID: 19675016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
    Jones ME
    Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogens resistant to antibacterial agents.
    Chen LF; Chopra T; Kaye KS
    Infect Dis Clin North Am; 2009 Dec; 23(4):817-45, vii. PubMed ID: 19909886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
    Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
    J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogens causing blood stream infections and their drug susceptibility profile in immunocompromised patients.
    Fayyaz M; Mirza IA; Ikram A; Hussain A; Ghafoor T; Shujat U
    J Coll Physicians Surg Pak; 2013 Dec; 23(12):848-51. PubMed ID: 24304986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Redesigning beta-lactams to combat resistance: summary and conclusions.
    Rossolini GM
    Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():30-3. PubMed ID: 17488374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Emergence pathogens infections in ENT Department of Children's hospital in 2005-2008].
    Zielnik-Jurkiewicz B; Rakowska-Szkudlarek M
    Otolaryngol Pol; 2009; 63(6):513-9. PubMed ID: 20198987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The current state of multidrug-resistant gram-negative bacilli in North America.
    Nicasio AM; Kuti JL; Nicolau DP
    Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Broad-spectrum beta-lactamases in Gram-negative bacteria].
    Sundsfjord A; Simonsen GS; Haldorsen B; Lundblad EW; Samuelsen O
    Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2741-5. PubMed ID: 19079424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.